NASDAQ, DXCM - Dexcom Inc
We are a medical device company focused on the design, development and
commercialization of continuous glucose monitoring systems for people with
diabetes. On March 24, 2006, we received approval from the U.S. Food and Drug
Administration, or FDA, for our first product, the Short-Term Continuous Glucose
Monitoring System, or STS ?, designed for up to three days of continuous use. On
May 31, 2007, we received approval from the FDA for our second generation
continuous glucose monitoring system, the SEVEN ?, designed for up to seven days
of continuous use, and we began commercializing this product in the third
quarter of 2007. As part of our commercialization of the SEVEN, we discontinued
sales of our STS three-day durable system in the second quarter of 2007. We
continue to sell three-day disposable sensors to customers who previously
purchased the STS durable system, and expect to discontinue sales of the
three-day sensors during 2008. ...
Read SEC Filing on NASDAQ.com »